TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01745224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revlite Q switched Nd:YAG
Description: Revlite Q switched Nd:YAG 1064nm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revlite Q switched Nd:YAG
Description: Revlite Q switched Nd:YAG 1064nm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trivantage Q switched Nd: YAG
Description: Trivantage Q switched Nd: YAG 1064nm
Study: NCT04446897

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: standard treatment according to clinical protocols
Study: NCT02536014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion (0.3㎍/kg/hr) from anesthetic induction to the end of pneumoperitoneum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline infusion during the same time period
Study: NCT03677011

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Andrositol® Test
Description: The intervention consists in the addiction of myo-inositol directly to the semen identifying the quality of sperm prior ICSI procedure

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Andrositol® Test
Description: The intervention consists in the addiction of myo-inositol directly to the semen identifying the quality of sperm prior ICSI procedure
Study: NCT01937039

Intervention type: PROCEDURE
Intervention: Sample collection
Description: Blood, tissue, urine, and other samples may be collected

Intervention type: PROCEDURE
Intervention: Sample collection
Description: Blood, tissue, urine, and other samples may be collected

Intervention type: PROCEDURE
Intervention: Sample collection
Description: Blood, tissue, urine, and other samples may be collected
Study: NCT04840277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote hearing aid adjustment
Description: The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
Study: NCT01396317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
Study: NCT03230110

Intervention type: DIAGNOSTIC_TEST
Intervention: WP200U home sleep study device
Description: WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.

Intervention type: DIAGNOSTIC_TEST
Intervention: WP200U home sleep study device
Description: WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
Study: NCT00287183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04494700 (TTP488)
Description: 60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02078947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise
Study: NCT01745224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trivantage Q switched Nd: YAG
Description: Trivantage Q switched Nd: YAG 1064nm
Study: NCT03303573

Intervention type: DRUG
Intervention: recombinant human erythropoietin
Description: Subcutaneous rhEPO injection
Study: NCT01683266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (Insulin glargine new formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (Insulin glargine)
Study: NCT00679029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously
Study: NCT02357160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artwork
Description: Prints by local artists that are hung on the walls of patient rooms.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Artwork
Description: Prints by local artists that are hung on the walls of patient rooms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Artwork
Description: Prints by local artists that are hung on the walls of patient rooms.
Study: NCT04379531

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose Chest CT
Description: Patients referred by the primary care physician with suspected pneumonia.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose Chest CT
Description: Patients referred by the primary care physician with suspected pneumonia.
Study: NCT03435536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
Study: NCT03118362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Description: Parenteral administration of Plasmalyte initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer lactate
Description: Parenteral administration of Ringer lactate initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days.
Study: NCT02949843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive other treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive other treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive other treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive other treatment
Study: NCT03156465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid L24
Description: Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
Study: NCT02676193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of Packaging on Smoking Perceptions and Behavior
Description: The intervention is the use of the assigned pack design.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of Packaging on Smoking Perceptions and Behavior
Description: The intervention is the use of the assigned pack design.
Study: NCT04447768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily
Study: NCT01381419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Single dose which may be split in up to three divided doses given 2 to 3 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
Study: NCT04109066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel (PTX)
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel (PTX)
Description: Specified dose on Specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nivolumab placebo
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anthracycline
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclophosphamide
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: Variable endocrine therapy of investigators choice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endocrine Therapy
Description: Variable endocrine therapy of investigators choice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery for breast cancer

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Surgery for breast cancer
Study: NCT01091402

Intervention type: PROCEDURE
Intervention: autologous serum skin test, serum IL-18

Intervention type: PROCEDURE
Intervention: autologous serum skin test, serum IL-18

Intervention type: PROCEDURE
Intervention: autologous serum skin test, serum IL-18

Intervention type: PROCEDURE
Intervention: autologous serum skin test, serum IL-18
Study: NCT02417532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation using REX
Description: Exercises of wheelchair dependent subjects using REX
Study: NCT02561286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRO HIV Risk Reduction Intervention
Description: BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Intervention
Description: Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals.
Study: NCT04894864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-Based Anesthesia-Analgesia Strategy
Description: A perioperative Opioid-Based multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Based arm of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-free Anesthesia-Analgesia Strategy
Description: A perioperative Opioid-Free multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Free arm of the study.
Study: NCT02949843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04577807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lerapolturev
Description: Lerapolturev administered via direct lesion injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lerapolturev
Description: Lerapolturev administered via direct lesion injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Checkpoint Inhibitor
Description: Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions
Study: NCT02949843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Molecular Therapy
Description: Receive drug targeting secondary mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor
Description: Given PO
Study: NCT04450524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food inhibition training
Description: Training the associations between foods and motor inhibition using a GO-NO-GO computer task.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A simple GO-NO-GO task
Study: NCT00004235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT03374696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFETY

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education
Study: NCT06730399

Intervention type: DEVICE
Intervention: Computed-assisted-cryotherapy
Description: cryotherapy device
Study: NCT02532179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mouse Allergenic Extract
Description: Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
Study: NCT00676130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~\> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~\> 80 kg (176 lbs): Cephalexin 1000 mg four times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~\> 80 kg (176 lbs): Cephalexin 1000 mg four times daily
Study: NCT02240108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin EIR
Description: Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Study: NCT02310555

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified gastric bypass.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Slevee Gastrectomy
Study: NCT03552133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart CO2
Description: A lightweight, cylindrical reservoir attached to a face mask which monitors breathing breath-by-breath and automatically adjusts the level of dead space rebreathe volume so that CO2 will be increased and sleep apnea treated.
Study: NCT04274959

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ceramic onlay with shoulder preparation design.
Description: ceramic onlay with shoulder preparation design which allowing the largest possible enamel for adhesion ,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ,ceramic onlay with butt joint preparation design
Description: ceramic onlay with butt joint preparation design with cusp reduction to protect teeth from occlusal loads and cuspal fracture
Study: NCT00953134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate (iron)
Description: 60 mg of ferrous fumarate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: 400 mcg folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: 400 mcg folic acid
Study: NCT02591095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Study: NCT03360916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor 20Mg Tablet
Description: One tablet by mouth every day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor 80Mg Tablet
Description: One tablet by mouth every day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo tablet by mouth every day for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program
Description: Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
Study: NCT02731937

Intervention type: DEVICE
Group type: OTHER
Intervention: GE Healthcare Revolution CT Scanner (CT Scanner)
Description: Raw CT Scan Data
Study: NCT02798549

Intervention type: OTHER
Group type: OTHER
Intervention: blood draw
Description: blood draw of 150ml, twice

Intervention type: OTHER
Group type: OTHER
Intervention: blood draw
Description: blood draw of 150ml, twice
Study: NCT02537002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: A single intravenous dose of 3 μg/kg
Study: NCT02078947

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Continuous Exercise

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Study: NCT03314233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DING
Description: Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol.
Study: NCT03800264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: PREVENTIVE DOUBLE BLINDED
Study: NCT02537002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: A single intravenous dose of 5 μg/kg
Study: NCT02423252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage, Relaxation, Guided imagery and music listening.
Description: In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)